TOBACCO FOR HEALTH WITH NEW PLANT BREEDING TECHNIQUES
BY: Diego Orzaez and MArkus ScHmidt
Public Release: 26-February 2018
IDOASIS 2002 SL participates in the EU-funded NEWCOTIANA project, a research and innovation action (RIA) that combines several new plant breeding techniques to produce medical and cosmetic products in tobacco plants.
- Taking advantage of cutting-edge molecular breeding methodologies, researchers will develop new varieties of tobacco and its wild relative Nicotiana benthamiana to produce added-value compounds such as antibodies, vaccines and drugs in a sustainable manner.
- NEWCOTIANA is a 7,2 M€ H2020 EU project coordinated by scientists at the Institute for Plant Molecular and Cellular Biology (IBMCP) from the Spanish Research Council (CSIC) with participation of 19 industrial and academic partners form 8 European countries and Australia.
Tobacco (Nicotiana tabacum) is a crop used to produce cigarettes. With overwhelming scientific evidence that smoking is harmful, even major cigarette companies are now committed to end smoking. Tobacco plants can, however, also be used for other purposes that are clearly beneficial for health. Instead of drying the leaves to make cigarettes, researchers have found promising New Plant Breeding Techniques (short: NPBT) to turn tobacco leaves into efficient plant factories for medical, pharmaceutical and cosmetic products. The same is true for the leaves of Nicotiana benthamiana, a dwarf tobacco relative from Australia which is especially suited for indoors production of bio-pharmaceuticals. In this way the plants will be bred to produce vaccines, antibodies, and other health-promoting substances including anti-aging or anti-inflammatory compounds.
The cutting-edge NPBTs include the so-called CRISPR technique, also known as genome editing, which offers unprecedented opportunities for crop breeding. Another NPBTs that researchers will apply are modern forms of grafting, or infiltration for temporary gene expression.
"We will breed new varieties of tobacco and Nicotiana benthamina that will work safely and efficiently as biofactories". Within NEWCOTIANA, "plants will be used as production platforms for molecular farming to harvest high value medical substances", explains Dr. Diego Orzaez from CSIC, coordinator of the NEWCOTIANA project.
By taking advantage of NPBTs, NEWCOTIANA is expected to contribute to revive the traditional cultivation of tobacco, creating new applications that are good for health, and revitalizing rural areas in decline with high-value products in line with the European Knowledge-Based Economy.
"The consortium will carry out experiments to assess the efficiency and safety of NPBTs, providing the industry, policy makers and consumers with experimental evidence that facilitate the decision-making process on the adoption of NPBTs in Europe. NEWCOTIANA's scientific aims are ambitious, and in addition to solving a number of technical issues we realize that also need to take into account regulatory requirements and start a dialogue with stakeholders and the general public.” adds Dr. Orzaez.
IDOASIS 2002, a biotechnology-based company strongly involved in the design of strategies to create multi-product integrated biorefineries, will have an important contribution to NEWCOTIANA by carrying out the extraction and purification of targeted secondary metabolites with important bioactivities. “The role of IDOASIS is to take the next step towards the industrialization of these biofactories, thus contributing to find an alternative for current tobacco crops” has pointed out Dr. Jose Carlos Quintela, Scientific Director of IDOASIS:
NEWCOTIANA, which was launched in February 2018 in Brussels, is a 4,5-year project funded by the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 760331.
Updates can be found at: newcotiana.org
For more information contact: Dr. Jose Carlos Quintela (IDOASIS):